In an attempt to maintain public safety and healthcare standards amidst the ongoing pandemic, the federal Drug Enforcement Administration (DEA) has issued another extension to its telehealth flexibilities. This move comes as part of the broader efforts to establish telemedicine as an effective and safe way to prescribe controlled substances during these disruptive times. The DEA’s Second Temporary Rule will now extend these flexibilities through December 31, 2024.
The decision to further extend these flexibilities is a response to the need to evaluate the best course of action moving forward. With the risk of COVID-19 largely overhead, telemedicine is rapidly becoming not only a convenient, but also a necessary strategy in the healthcare field. The DEA’s recent issue of the Second Temporary Rule exhibits its recognition of the situation and its commitment to adapting to these new challenges in the short and mid-term.
The real test, however, lies in the implementation and utilization of telemedicine in the long run. The DEA’s temporary ruling endorses a practical and flexible approach towards telehealth practise, providing controlled substance prescriptions to patients who may not be able to make in-person visits due to the ongoing pandemic.
Only time will tell how this extended policy will impact both healthcare providers and the patients they serve. Professional healthcare communities and the DEA will have to continue their coordination for the smooth facilitation of these changes. To some, this extension could be indicative of a potential shift towards a more permanent role for telemedicine in the prescription of controlled substances.
For more in-depth coverage of this decision, take a look at the full article on JD Supra.